Introduction
The octapeptide hormone angiotensin II (Ang II, Asp 1 8 ) is the primary effector of the renin-angiotensin system. The Ang II type 1 (AT1) receptor has a widespread tissue distribution and mediates most known cardiovascular functions including vasoconstriction, cardiovascular hypertrophy and hyperplasia (1, 2) .
The major features of Ang II that determine its biological activity were identified in early in vivo and in vitro studies with structurally modified Ang II peptides (3) . The biological activity of Ang II is highly dependent on the aromaticity of its Phe 8 C-terminal residue. In recent mutagenesis studies, agonist-induced activation of the AT1 receptor appeared to previous report also indicated that specific substitutions did not equally inhibit IP production, receptor phosphorylation and extracellular-signal-regulated kinase (ERK) activation (10 8 ]Ang II for a Gq-dependent pathway was shown to activate p-ERK, which is a key component of blood vessels and induces coronary constriction and cell growth, in human coronary artery smooth muscle cells (HCSMCs). Moreover, we demonstrated that Ang II induced two different signals through the AT1 receptor at the same time: vasoconstriction through a Gq-dependent pathway, and the regulation of cell growth through a Gq-independent epidermal growth factor (EGF) receptor transactivation. A clear understanding of these two pathways may be necessary for the development of therapeutic agents to treat disorders such as hypertension and cardiac hypertrophy, and these two different pathological pathways may need to be therapeutically regulated in vivo.
Methods

Materials
The following antibodies and reagents were generously provided as indicated or purchased: anti-ERK 1/2 antibody and ERK inhibitor, PD98059 (New England Biolabs, Beverly, USA), anti-p-ERK 1/2 antibody (Promega, Madison, USA), and the EGF receptor kinase inhibitor AG1478 (Sigma, St. Louis, USA). Ang II analogues were purchased from Bachem (Bubendorf, Switzerland).
Mutagenesis and Expression of the AT1 Receptor
The pcDNA3-AT1 receptor-enhanced green fluorescent protein (EGFP; Clontech, Palo Alto, USA) expression vector was constructed by fusion of the coding sequence of EGFP to the 3 end of the AT1 receptor coding sequence. Cells were transfected using 1,3-di-oleoyloxy-2-(6-carboxyspermyl)-propylamide (DOSPER) liposomal reagent (Boehringer Mannheim, Indianapolis, USA). Positive clones were selected by G418 and evaluated by a Fluorescence Activated Cell Sorter (FACS) (Vantage; Becton Dickinson, San Jose, USA; a gift from the Keck Foundation). Cells that had been cultured for 48 h were harvested and cell membranes were prepared by the nitrogen parbomb disruption method. Receptor expression was assessed in each case by immunoblot analysis (not shown) and by 125 I-[Sar 1 , Ile 8 ]Ang II saturation binding analysis.
Cell Cultures and Treatments
HCSMCs were purchased from Clonetics (San Diego, USA). HCSMCs were cultured in smooth muscle cell (SMC) growth medium (SMGM) (Clonetics) supplemented with 5% fetal bovine serum (FBS), penicillin/streptomycin, and SMC growth supplement (Takara Co., Tokyo, Japan) at 37°C in 5% CO2. Chinese hamster ovary cells, CHO-K1 (American Type Culture Collection, Rockville, USA), were cultured using Dulbecco's modified Eagle's essential medium (DMEM) with 10% FBS (HyClone, Logan, USA) in 5% CO2 at 37°C.
Receptor Binding Assay
The ligand binding experiments were carried out as described previously (4, 5 
IP Formation Studies
Total soluble IP was measured by the perchloric acid extraction method, as described previously (4, 5) .
Cell Proliferation Assay
HCSMCs (5 10 3 ) were plated on a 96-well plate and cultured under 5% serum conditions. After 48 h, the cells were cultured for 18 h in the presence or absence of the indicated concentrations of analogues in DMEM supplemented with 0.1% FBS at 37°C in 5% CO2. After 18 h, the cells were stained with CellTiter 96 One Solution Reagent (a novel tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS assay] (Promega) for 2 h at 37°C in 5% CO2, and the absorbance at 490 nm was recorded with a 96-well plate reader.
Immunoblotting
Immunoblotting was performed with primary antibodies as specified in each case, as described previously (12) . ERK activity was measured in cells maintained for 18 h in DMEM containing 0.1% serum. Horseradish peroxidase-conjugated secondary antibody and the enhanced chemiluminescent substrate system (Amersham, Buckinghamshire, UK) were used. The signal was independently quantified by digital image analysis.
Statistical Analysis
The results are expressed as the mean SEM of three or more independent determinations. The significance of differences between measured values was evaluated by an analysis of variance with Bonferroni's test and unpaired Student's t-test. Statistical significance was set at the level of p<0.05.
Results
IP Production in a CHO-K1 Cell Line Expressing AT1 Receptor-EGFP
A cell model in which the level of AT1 receptor expression can be controlled is better suited for this study because it is difficult to quantitate p-ERK 1/2 activity using various Ang II analogues. Therefore, we established a CHO-K1 cell line that stably expressed the AT1 receptor as a surrogate model (Fig. 2B) (Fig. 2D) . (Fig. 3A, B) . These results were consistent with previous studies in surrogate cell models (10, 11) . Interstingly, [Sar 1 , Ile 4 , Ile 8 ]Ang II-induced p-ERK 1/2 activation was completely blocked by PD98059 and mostly blocked by AG1487 (Fig. 3A, B 
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